At QurCan Therapeutics (www.QurCan.com), we have developed a novel nanoparticle drug delivery platform 'TERP' (Target-Engineered Responsive Polymer), designed to enable delivery of genetic medicines to extrahepatic tissues, including the Brain and the Spleen TERP is a hybrid polymer-lipid nanoparticle system, enabling non-immunogenic, repeated, intravenous administration of nucleotide payloads (ASO, siRNA, mRNA, DNA) and very effective brain delivery. The technology has been validated in various preclinical and IND-enabling studies, including in non-human primates, and through collaborations with top-5 pharmaceutical companies. We’re working with biopharma partners, leading research institutions and investors to develop the next generation tissue-targeted genetic medicines to prevent, slow, or stop progression of deadly neurodegenerative diseases and cancers.